ViCentra adds $13m in second close of Series D funding round
Bringing its total Series D funds to $98m, ViCentra plans to boost manufacturing capabilities for its Kaleido insulin pump and prepare for a US market entry.
08 January 2026
08 January 2026
Bringing its total Series D funds to $98m, ViCentra plans to boost manufacturing capabilities for its Kaleido insulin pump and prepare for a US market entry.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.